Loading...
•
Dec 31, 2024
Intellia Q4 2024 Earnings Report
Reported operational highlights and financial results.
Key Takeaways
Intellia Therapeutics reported its Q4 and full-year 2024 financial results, highlighting the dosing of the first patient in the global Phase 3 HAELO study for NTLA-2002 and the continued progress of the Phase 3 MAGNITUDE trial for nexiguran ziclumeran. The company ended the year with approximately $862 million in cash, cash equivalents, and marketable securities.
Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE).
Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027.
Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year end.
Ended 2024 with approximately $862 million in cash, cash equivalents and marketable securities.
Revenue by Segment
Forward Guidance
Intellia Therapeutics is prioritizing late-stage programs and expects to incur charges of approximately $8.0 million for severance and other employee termination-related costs in the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...